View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 9/1: (JCP) (BSX) (WEX) Upgraded; (PNR) (ISIL) Downgraded
-
Ideal Power to Participate at Upcoming Investor Conferences
-
Roth Capital Starts Cypress Semi (CY) at Buy
-
Roth Capital Assumes Intel (INTC) at Buy
-
Roth Capital Assumes InvenSense (INVN) at Buy
-
Roth Capital Assumes QuickLogic (QUIK) at Buy
-
Roth Capital Starts Rambus Inc. (RMBS) at Buy
-
Roth Capital Starts DSP Group (DSPG) at Buy
-
Roth Capital Starts Applied Micro Circuits (AMCC) at Buy
-
Roth Capital Assumes Adesto Technologies (IOTS) at Buy
-
ROTH Capital Partners to Host Solar & Storage Symposium at Solar Power International
-
Lucas Energy Closes Acquisition Transaction And Related Financings
-
Lucas Energy Closes Acquisition Transaction And Related Financings
-
Notable Analyst Rating Changes 8/29: (CBL) (ATI) (KS) Upgraded; (HAYN) (KEY) (SQ) Downgraded
-
UPDATE: Roth Capital Starts Neuralstem (CUR) at Buy
-
Form X-17A-5 ROTH CAPITAL PARTNERS, For: Jun 30
-
MaxLinear, Inc. to Present at Upcoming Financial Conferences
-
Emerging Solar Markets Remain Key for JinkoSolar (JKS); Roth Capital Affirms at 'Neutral'
-
Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
-
Notable Analyst Rating Changes 8/25: (LLL) (RIG) (NFLX) Upgraded; (S) (OZM) (DDR) Downgraded
-
Roth Capital Keeps Prima BioMed (PBMD) at 'Buy' Following Receipt of IMP731-Related European Patent
-
ROTH Capital Partners to Host Datacenter Technology Corporate Access Day in San Francisco, Calif. on September 7, 2016
-
Roth Capital Downgrades PCM, Inc (PCMI) to Neutral
-
Roth Sees Lion Biotech's (LBIO) NCI Announcement as Important Given Impact on Thesis; Affirms at 'Buy'
-
Roth Capital Starts Actinium Pharma (ATNM) at Buy, PT $5
-
Roth Capital Starts Acuity Brands (AYI) at Neutral; Sees Bar Set High for Market Leader
-
Roth Capital Assumes LSI Industries (LYTS) at Buy; Positive on New Management, Down Lighting Opportunity
-
Roth Capital Starts Cree (CREE) at Buy; Positive on Growth Outlook for Lighting Products Unit
-
Hudson Technologies (HDSN) Sees Continued Momentum as Hot Summer Weather Lingers - Roth Capital
-
Roth Affrims Trina Solar (TSL) at 'Neutral'; Industry Supply-Demand Imbalances Mar Visibility
-
Roth Capital Reiterates $32 PT on Stemline Therapeutics (STML) as Breakthrough Therapy Granted
-
Roth Capital Doubles PT on Clean Diesel Technologies (CDTI) to $4; Sees Improving Balance Sheet Metrics
-
Roth Capital Positive on Sky Solar's (SKYS) Move to Sell Japanese Solar Project Assets; Affirms at 'Buy'
-
Notable Analyst Rating Changes 8/22: (BRX) (HRL) (VNCE) Upgraded; (RLYP) (WDAY) (TRNO) Downgraded
-
Notable Mergers and Acquisitions 8/22: (PFE)/(MDVN) (CST) (CIFC) (MOBI)
-
Sky-mobi Limited (MOBI) Enters 'Going Private' Deal at $2.20/ADS
-
Sky-mobi Limited Enters into Definitive Agreement for Going Private Transaction
-
Roth Capital Starts Platform Specialty Products (PAH) at Buy
-
Roth Sees Canadian Solar's (CSIQ) Cost Management Actions Panning Out; Affirms at 'Buy'
-
Roth Capital Sees Ballard Power's (BLDP) Deal with Toyota as 'Significant' Positive; Affirms at 'Buy'
-
Roth Capital Cuts PT on Cerulean Pharma (CERU) to $2.50 Following CRLX101 Combo Phase 2 Data
-
Roth Capital Positive on Cytokinetics (CYTK) Following 'Milestone' ALS Study Enrollment
-
Roth Says Quest Resource (QRHC) Q2 Results Inline, but SG&A Continues to Run High
-
Roth Capital Keeps Heat Biologics (HTBX) at 'Buy' at Q4 Inflection Points Near
-
Zosano Pharma (ZSAN) Prices Common Stock, Warrants Private Placement at $1.57/Unit
-
Zosano Pharma Announces Pricing of Private Placement of Common Stock and Warrants
-
Roth Capital Keeps VBL Therapeutics (VBLT) at 'Buy' Following Q2 Results; Glioblastoma Remains in Focus
-
Roth Capital Trims PT on Plug Power (PLUG) to $1.75 Following Q2 Report
-
Roth Capital Says, Amid Global Water's (GWRS) Muddle Q2, Key Catalysts Approach
-
Roth Keeps Ballard Power (BLDP) at 'Buy' Following Meetings with Management; Positive on Telecom Sale

